Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2009

01-02-2009 | Original Article

Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans

Authors: Eun-Kyung Park, June-Key Chung, Il Han Lim, Do Joon Park, Dong Soo Lee, Myung Chul Lee, Bo Youn Cho

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2009

Login to get access

Abstract

Purpose

Serum Tg and I-131 WBS have been used to detect recurrent and metastatic thyroid cancers postoperatively. Tg is known to be more sensitive than I-131 WBS, and therefore, false-negative WBS cases with elevated Tg levels are frequently found. However, the clinical characteristics of false-negative Tg cases with positive WBS have not been clarified.

Materials and methods

The authors evaluated 824 postoperative patients with differentiated thyroid carcinoma who underwent post-ablation/therapy I-131 WBS. Tg negativity was defined as a Tg level of ≤2 ng/mL without TgAb under thyroid-stimulating hormone stimulation. Remission, recurrence, and metastasis were confirmed using pathologic or clinically findings.

Results

Fifty-two patients (6.3%) with functioning metastasis and negativity for TgAb were Tg-negative and posttherapy I-131 WBS-positive (TgN group), and 128 patients with functioning metastases were Tg positive and WBS positive (TgP group). The TgN group consisted of 45 cases of cervical/mediastinal lymph node metastases (86.5%) and seven cases of distant metastasis to lung or bone by follow-up WBS. The TgN group demonstrated significantly higher profiles of regional involvement than the TgP group (P < 0.029). In 47 patients in the TgN group, metastatic uptake disappeared in 33, ameliorated in four, and persisted in ten during follow-up.

Conclusions

A significant number of differentiated thyroid cancer patients were Tg-/TgAb-negative despite a positive WBS finding. Cervical and mediastinal lymph nodes were predominant sites of metastasis in the TgN group. WBS should be undertaken routinely as a complementary modality to detect functioning recurrence and metastasis regardless of serum Tg results.
Literature
1.
go back to reference Saghari M, Gholamrezanezhad A, Mirpour S, Eftekhari M, Takavar A, Fard-Esfahani A, et al. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan. Nucl Med Commun 2006;27:567–72.PubMedCrossRef Saghari M, Gholamrezanezhad A, Mirpour S, Eftekhari M, Takavar A, Fard-Esfahani A, et al. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan. Nucl Med Commun 2006;27:567–72.PubMedCrossRef
2.
go back to reference Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999;22:3–7.PubMed Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999;22:3–7.PubMed
3.
go back to reference Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000;10:767–78.PubMed Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000;10:767–78.PubMed
4.
go back to reference Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979;20:92–7.PubMed Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979;20:92–7.PubMed
5.
go back to reference Lee BW, Lee DS, Moon DH, Chung JK, Lee MC, Cho BY, et al. Comparison of I-131 diagnostic scan and therapeutic scan in thyroid carcinoma. Korean J Nucl Med 1990;24:80–6. Lee BW, Lee DS, Moon DH, Chung JK, Lee MC, Cho BY, et al. Comparison of I-131 diagnostic scan and therapeutic scan in thyroid carcinoma. Korean J Nucl Med 1990;24:80–6.
6.
go back to reference Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433–41.PubMedCrossRef Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433–41.PubMedCrossRef
7.
go back to reference Pagano L, Klain M, Pulcrano M, Angellotti G, Pasano F, Salvatore M, et al. Follow-up of differentiated thyroid carcinoma. Minerva Endocrinol 2004;29:161–74.PubMed Pagano L, Klain M, Pulcrano M, Angellotti G, Pasano F, Salvatore M, et al. Follow-up of differentiated thyroid carcinoma. Minerva Endocrinol 2004;29:161–74.PubMed
8.
go back to reference Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105–12.PubMedCrossRef Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105–12.PubMedCrossRef
9.
go back to reference Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.PubMedCrossRef Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.PubMedCrossRef
10.
go back to reference Pellegriti G, Scollo C, Regalbuto C, Attard M, Marozzi P, Vermiglio F, et al. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endocrinol (Oxf) 2003;58:556–61.CrossRef Pellegriti G, Scollo C, Regalbuto C, Attard M, Marozzi P, Vermiglio F, et al. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endocrinol (Oxf) 2003;58:556–61.CrossRef
11.
go back to reference Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med 2005;46:1473–80.PubMed Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med 2005;46:1473–80.PubMed
12.
go back to reference Mariotti S, Cupini C, Giani C, Lari R, Rolleri E, Falco A, et al. Evaluation of a solid-phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of anti-thyroglobulin autoantibody. Clin Chim Acta 1982;123:347–55.PubMedCrossRef Mariotti S, Cupini C, Giani C, Lari R, Rolleri E, Falco A, et al. Evaluation of a solid-phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of anti-thyroglobulin autoantibody. Clin Chim Acta 1982;123:347–55.PubMedCrossRef
13.
go back to reference Rubello D, Girelli ME, Casara D, Piccolo M, Perin A, Busnardo B. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 1990;13:737–42.PubMed Rubello D, Girelli ME, Casara D, Piccolo M, Perin A, Busnardo B. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 1990;13:737–42.PubMed
14.
go back to reference Schulz R, Bethauser H, Stempka L, Heilig B, Moll A, Hufner M. Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men. Eur J Clin Invest 1989;19:459–63.PubMedCrossRef Schulz R, Bethauser H, Stempka L, Heilig B, Moll A, Hufner M. Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men. Eur J Clin Invest 1989;19:459–63.PubMedCrossRef
15.
go back to reference Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988;61:976–81.PubMedCrossRef Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988;61:976–81.PubMedCrossRef
16.
go back to reference Mertens IJ, De Klerk JM, Zelissen PM, Thijssen JH, Sie-Go DM, Han SH, et al. Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer. Clin Nucl Med 1999;24:346–9.PubMedCrossRef Mertens IJ, De Klerk JM, Zelissen PM, Thijssen JH, Sie-Go DM, Han SH, et al. Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer. Clin Nucl Med 1999;24:346–9.PubMedCrossRef
17.
go back to reference Brendel AJ, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P, et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 1990;16:35–8.PubMedCrossRef Brendel AJ, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P, et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 1990;16:35–8.PubMedCrossRef
18.
go back to reference Grant S, Luttrell B, Reeve T, Wiseman J, Wilmshurst E, Stiel J, et al. Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer 1984;54:1625–8.PubMedCrossRef Grant S, Luttrell B, Reeve T, Wiseman J, Wilmshurst E, Stiel J, et al. Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer 1984;54:1625–8.PubMedCrossRef
19.
go back to reference Morgenthaler NG, Froehlich J, Rendl J, Willnich M, Alonso C, Bergmann A, et al. Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin. Clin Chem 2002;48:1077–83.PubMed Morgenthaler NG, Froehlich J, Rendl J, Willnich M, Alonso C, Bergmann A, et al. Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin. Clin Chem 2002;48:1077–83.PubMed
20.
go back to reference Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12:707–11.PubMedCrossRef Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12:707–11.PubMedCrossRef
21.
go back to reference Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007;17:1085–92.PubMedCrossRef Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007;17:1085–92.PubMedCrossRef
22.
go back to reference Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003;237:399–407.PubMedCrossRef Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003;237:399–407.PubMedCrossRef
23.
go back to reference Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:1448–52.PubMedCrossRef Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:1448–52.PubMedCrossRef
24.
go back to reference Shah DH, Dandekar SR, Jeevanram RK, Kumar A, Sharma SM, Ganatra RD. Serum thyroglobulin differentiated thyroid carcinoma: histological and metastatic classification. Acta Endocrinol (Copenh) 1981;98:222–6. Shah DH, Dandekar SR, Jeevanram RK, Kumar A, Sharma SM, Ganatra RD. Serum thyroglobulin differentiated thyroid carcinoma: histological and metastatic classification. Acta Endocrinol (Copenh) 1981;98:222–6.
25.
go back to reference Alzahrani AS, Bakheet S, Al Mandil M, Al-Hajjaj A, Almahfouz A, Al Haj A. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning. J Clin Endocrinol Metab 2001;86:5294–300.PubMedCrossRef Alzahrani AS, Bakheet S, Al Mandil M, Al-Hajjaj A, Almahfouz A, Al Haj A. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning. J Clin Endocrinol Metab 2001;86:5294–300.PubMedCrossRef
26.
go back to reference Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 2007;34:1012–7.PubMedCrossRef Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 2007;34:1012–7.PubMedCrossRef
27.
go back to reference Rault E, Vandenberghe S, Van Holen R, De Beenhouwer J, Staelens S, Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm 2007;22:423–30.PubMedCrossRef Rault E, Vandenberghe S, Van Holen R, De Beenhouwer J, Staelens S, Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm 2007;22:423–30.PubMedCrossRef
28.
go back to reference Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002;37:169–74.PubMedCrossRef Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002;37:169–74.PubMedCrossRef
29.
go back to reference Iervasi A, Iervasi G, Bottoni A, Boni G, Annicchiarico C, Di Cecco P, et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J Endocrinol 2004;182:287–94.PubMedCrossRef Iervasi A, Iervasi G, Bottoni A, Boni G, Annicchiarico C, Di Cecco P, et al. Diagnostic performance of a new highly sensitive thyroglobulin immunoassay. J Endocrinol 2004;182:287–94.PubMedCrossRef
30.
go back to reference Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999;9:435–41.PubMedCrossRef Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999;9:435–41.PubMedCrossRef
Metadata
Title
Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans
Authors
Eun-Kyung Park
June-Key Chung
Il Han Lim
Do Joon Park
Dong Soo Lee
Myung Chul Lee
Bo Youn Cho
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0912-0

Other articles of this Issue 2/2009

European Journal of Nuclear Medicine and Molecular Imaging 2/2009 Go to the issue